Based on the Aligos Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Aligos Therapeutics Inc is not available over the next 12 months. Aligos Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aligos Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Aligos Therapeutics Inc’s stock price was USD 5.83. Aligos Therapeutics Inc’s stock price has changed by +24.57% over the past week, -49.87% over the past month and -71.87% over the last year.
No recent analyst target price found for Aligos Therapeutics Inc
No recent average analyst rating found for Aligos Therapeutics Inc
Company Overview Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Read Less
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical tri...Read More
Frequently Asked Questions About Aligos Therapeutics Inc (ALGS) Stock
Stock Target Advisor's fundamental analysis for Aligos Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on ALGS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ALGS's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ALGS's stock to indicate if its overvalued.
The last closing price of ALGS's stock was USD 5.83.
The most recent market capitalization for ALGS is USD 0.06B.
Unfortunately we do not have enough analyst data on ALGS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aligos Therapeutics Inc's stock.
As per our most recent records Aligos Therapeutics Inc has 70 Employees.
Aligos Therapeutics Inc's registered address is One Corporate Drive, South San Francisco, CA, United States, 94080.
You can get more information about it from Aligos Therapeutics Inc's website at https://www.aligos.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Aligos Therapeutics Inc (ALGS) Stock
Stock Target Advisor's fundamental analysis for Aligos Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on ALGS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ALGS's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ALGS's stock to indicate if its overvalued.
The last closing price of ALGS's stock was USD 5.83.
The most recent market capitalization for ALGS is USD 0.06B.
Unfortunately we do not have enough analyst data on ALGS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aligos Therapeutics Inc's stock.
As per our most recent records Aligos Therapeutics Inc has 70 Employees.
Aligos Therapeutics Inc's registered address is One Corporate Drive, South San Francisco, CA, United States, 94080.
You can get more information about it from Aligos Therapeutics Inc's website at https://www.aligos.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALGS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
